Overlap chronic GVHD is associated with adverse survival outcomes compared to classic chronic GVHD.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
21 Feb 2024
21 Feb 2024
Historique:
received:
07
08
2023
accepted:
07
02
2024
revised:
20
12
2023
medline:
22
2
2024
pubmed:
22
2
2024
entrez:
21
2
2024
Statut:
aheadofprint
Résumé
Chronic graft-versus-host-disease (cGVHD) is divided into two subtypes: classic (absence of acute GVHD features) and overlap cGVHD ('ocGVHD'), in which both chronic and acute GVHD clinical features are present simultaneously. While worse outcomes with ocGVHD have been reported, there are few recent analyses. We performed a secondary analysis of data from the ABA2 trial (N = 185), in which detailed GVHD data were collected prospectively and systematically adjudicated. Analyses included cumulative incidence of classic versus ocGVHD, their specific organ manifestations, global disease severity scores, non-relapse mortality (NRM), disease-free survival (DFS) and overall survival (OS) in these two cGVHD subtypes. Of 92 patients who developed cGVHD, 35 were classified as ocGVHD. The 1-year cumulative incidence, organ involvement, and global severity of classic and ocGVHD were similar between ABA2 patients receiving CNI/MTX+placebo and CNI/MTX+abatacept; thus, cohorts were combined for ocGVHD evaluation. This analysis identified ocGVHD as having significantly higher severity at presentation and at maximum global severity compared to classic cGVHD. OS and DFS were significantly lower for ocGVHD versus classic cGVHD. OcGVHD is associated with increased cGVHD severity scores, and is associated with decreased OS and DFS compared to classic cGVHD, underscoring the high risks with this cGVHD subtype.
Identifiants
pubmed: 38383714
doi: 10.1038/s41409-024-02245-y
pii: 10.1038/s41409-024-02245-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Lee SJ, Flowers ME. Recognizing and managing chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program. 2008;1:134-41.
Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR, et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transpl. 2015;21:266–74.
doi: 10.1016/j.bbmt.2014.10.021
Flowers ME, Inamoto Y, Carpenter PA, Lee SJ, Kiem HP, Petersdorf EW, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011;117:3214–9.
doi: 10.1182/blood-2010-08-302109
pubmed: 21263156
pmcid: 3062319
Saliba RM, Alousi AM, Pidala J, Arora M, Spellman SR, Hemmer MT, et al. Characteristics of graft-versus-host disease (GvHD) after post-transplantation cyclophosphamide versus conventional GvHD prophylaxis. Transpl Cell Ther. 2022;28:681–93.
doi: 10.1016/j.jtct.2022.07.013
Zeiser R, Blazar BR. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med. 2017;377:2565–79.
doi: 10.1056/NEJMra1703472
pubmed: 29281578
Ryan CE, Sahaf B, Logan AC, O’Brien S, Byrd JC, Hillmen P, et al. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood. 2016;128:2899–908.
doi: 10.1182/blood-2016-06-715284
pubmed: 27802969
pmcid: 5179333
Cutler C, Lee SJ, Arai S, Rotta M, Zoghi B, Lazaryan A, et al. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood. 2021;138:2278–89.
doi: 10.1182/blood.2021012021
pubmed: 34265047
pmcid: 8641099
Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, et al. Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. N Engl J Med. 2021;385:228–38.
doi: 10.1056/NEJMoa2033122
pubmed: 34260836
Inamoto Y, Flowers ME, Sandmaier BM, Aki SZ, Carpenter PA, Lee SJ, et al. Failure-free survival after initial systemic treatment of chronic graft-versus-host disease. Blood. 2014;124:1363–71.
doi: 10.1182/blood-2014-03-563544
pubmed: 24876566
pmcid: 4141518
Zeiser R, Lee SJ. Three US Food and Drug Administration-approved therapies for chronic GVHD. Blood. 2022;139:1642–5.
doi: 10.1182/blood.2021014448
pubmed: 35081254
pmcid: 8931512
Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transpl. 2015;21:389–401.e1.
doi: 10.1016/j.bbmt.2014.12.001
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transpl. 2005;11:945–56.
doi: 10.1016/j.bbmt.2005.09.004
Sato T, Ichinohe T, Kanda J, Yamashita K, Kondo T, Ishikawa T, et al. Clinical significance of subcategory and severity of chronic graft-versus-host disease evaluated by National Institutes of Health consensus criteria. Int J Hematol. 2011;93:532–41.
doi: 10.1007/s12185-011-0820-0
pubmed: 21465116
Moon JH, Sohn SK, Lambie A, Ellis L, Hamad N, Uhm J, et al. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival. Biol Blood Marrow Transpl. 2014;20:556–63.
doi: 10.1016/j.bbmt.2014.01.010
Arora M, Nagaraj S, Witte J, DeFor TE, MacMillan M, Burns LJ, et al. New classification of chronic GVHD: added clarity from the consensus diagnoses. Bone Marrow Transpl. 2009;43:149–53.
doi: 10.1038/bmt.2008.305
Kim DY, Lee JH, Lee JH, Kim SH, Lim SN, Kim SD, et al. Reevaluation of the National Institutes of Health criteria for classification and scoring of chronic GVHD. Bone Marrow Transpl. 2010;45:1174–80.
doi: 10.1038/bmt.2009.320
Cuvelier GDE, Nemecek ER, Wahlstrom JT, Kitko CL, Lewis VA, Schechter T, et al. Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria. Blood. 2019;134:304–16.
doi: 10.1182/blood.2019000216
pubmed: 31043425
pmcid: 6911839
Takahashi T, Arora M, Okoev G, DeFor TE, Weisdorf DJ, MacMillan ML. Late-onset acute and chronic graft-versus-host disease in children: clinical features and response to therapy. Transplant Cell Ther. 2021;27:667.e1–e5.
doi: 10.1016/j.jtct.2021.05.022
pubmed: 34077812
Pidala J, Vogelsang G, Martin P, Chai X, Storer B, Pavletic S, et al. Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study. Haematologica. 2012;97:451–8.
doi: 10.3324/haematol.2011.055186
pubmed: 22058206
pmcid: 3291602
Arora M, Pidala J, Cutler CS, Chai X, Kurland B, Jacobsohn DA, et al. Impact of prior acute GVHD on chronic GVHD outcomes: a chronic graft versus host disease consortium study. Leukemia. 2013;27:1196–201.
doi: 10.1038/leu.2012.292
pubmed: 23047477
Cho BS, Min CK, Eom KS, Kim YJ, Kim HJ, Lee S, et al. Feasibility of NIH consensus criteria for chronic graft-versus-host disease. Leukemia. 2009;23:78–84.
doi: 10.1038/leu.2008.276
pubmed: 18830253
Perez-Simon JA, Encinas C, Silva F, Arcos MJ, Diez-Campelo M, Sanchez-Guijo FM, et al. Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the national institutes health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy. Biol Blood Marrow Transpl. 2008;14:1163–71.
doi: 10.1016/j.bbmt.2008.07.015
Jagasia M, Giglia J, Chinratanalab W, Dixon S, Chen H, Frangoul H, et al. Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria. Biol Blood Marrow Transpl. 2007;13:1207–15.
doi: 10.1016/j.bbmt.2007.07.001
Aisa Y, Mori T, Kato J, Yamane A, Kohashi S, Kikuchi T, et al. Validation of NIH consensus criteria for diagnosis and severity-grading of chronic graft-versus-host disease. Int J Hematol. 2013;97:263–71.
doi: 10.1007/s12185-013-1268-1
pubmed: 23371545
Kuzmina Z, Eder S, Bohm A, Pernicka E, Vormittag L, Kalhs P, et al. Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study. Leukemia. 2012;26:746–56.
doi: 10.1038/leu.2011.257
pubmed: 21926960
Lueck C, Tzalavras A, Wohlfarth P, Meedt E, Kiehl M, Turki AT, et al. Impact of chronic graft-versus-host-disease on intensive care outcome in allogeneic hematopoietic stem cell recipients. Bone Marrow Transpl. 2023;58:303–10.
Hamilton BK, Rybicki L, Arai S, Arora M, Cutler CS, Flowers MED, et al. Association of socioeconomic status with chronic graft-versus-host disease outcomes. Biol Blood Marrow Transpl. 2018;24:393–9.
doi: 10.1016/j.bbmt.2017.10.009
Csanadi M, Agh T, Tordai A, Webb T, Jeyakumaran D, Sengupta N, et al. A systematic literature review of incidence, mortality, and relapse of patients diagnosed with chronic graft versus host disease. Expert Rev Hematol. 2019;12:311–23.
doi: 10.1080/17474086.2019.1605288
pubmed: 30955381
Okoev G, Weisdorf DJ, Wagner JE, Blazar BR, MacMillan ML, DeFor T, et al. Outcomes of chronic graft-versus-host disease following matched sibling donor versus umbilical cord blood transplant. Bone Marrow Transpl. 2021;56:1373–80.
doi: 10.1038/s41409-020-01195-5
Schultz KR, Kariminia A, Ng B, Abdossamadi S, Lauener M, Nemecek ER, et al. Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studies. Blood. 2020;135:1287–98.
doi: 10.1182/blood.2019003186
pubmed: 32047896
pmcid: 7146024
Tang FF, Cheng YF, Xu LP, Zhang XH, Yan CH, Han W, et al. Incidence, risk factors, and outcomes of chronic graft-versus-host disease in pediatric patients with hematologic malignancies after T cell-replete myeloablative haploidentical hematopoietic stem cell transplantation with antithymocyte globulin/granulocyte colony-stimulating factor. Biol Blood Marrow Transpl. 2020;26:1655–62.
doi: 10.1016/j.bbmt.2020.05.021
Cuvelier GDE, Ng B, Abdossamadi S, Nemecek ER, Melton A, Kitko CL, et al. A diagnostic classifier for pediatric chronic graft-versus-host disease: results of the ABLE / PBMTC 1202 study. Blood Adv. 2023;7:3612–23.
Watkins B, Qayed M, McCracken C, Bratrude B, Betz K, Suessmuth Y, et al. Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD. J Clin Oncol. 2021;39:1865–77.
doi: 10.1200/JCO.20.01086
pubmed: 33449816
pmcid: 8260909
Schoemans HM, Lee SJ, Ferrara JL, Wolff D, Levine JE, Schultz KR, et al. EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transpl. 2018;53:1401–15.
doi: 10.1038/s41409-018-0204-7
Pusic I, Pavletic SZ. Challenges in conducting studies in chronic graft-versus-host disease. Clin Hematol Int. 2019;1:36–44.
doi: 10.2991/chi.d.190314.001
pubmed: 34595409
pmcid: 8432377
Holtan SG, Khera N, Levine JE, Chai X, Storer B, Liu HD, et al. Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors. Blood. 2016;128:2350–8.
doi: 10.1182/blood-2015-09-669846
pubmed: 27625357
pmcid: 5106113
Moon JH, Kim SN, Kang BW, Chae YS, Kim JG, Ahn JS, et al. Early onset of acute GVHD indicates worse outcome in terms of severity of chronic GVHD compared with late onset. Bone Marrow Transpl. 2010;45:1540–5.
doi: 10.1038/bmt.2010.12
Omer AK, Weisdorf DJ, Lazaryan A, Shanley R, Blazar BR, MacMillan ML, et al. Late acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2016;22:879–83.
doi: 10.1016/j.bbmt.2015.12.020
Vigorito AC, Campregher PV, Storer BE, Carpenter PA, Moravec CK, Kiem HP, et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood. 2009;114:702–8.
doi: 10.1182/blood-2009-03-208983
pubmed: 19470693
pmcid: 2713471
Lee SE, Cho BS, Kim JH, Yoon JH, Shin SH, Yahng SA, et al. Risk and prognostic factors for acute GVHD based on NIH consensus criteria. Bone Marrow Transpl. 2013;48:587–92.
doi: 10.1038/bmt.2012.187
Akahoshi Y, Spyrou N, Hogan WJ, Ayuk F, DeFilipp Z, Weber D, et al. Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD. Blood Adv. 2023;7:4479–91.
doi: 10.1182/bloodadvances.2023009885
pubmed: 37315175
pmcid: 10440469